Batavia Biosciences’ Post

𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗶𝗻𝗴 𝗮 𝗡𝗘𝗪 𝗪𝗵𝗶𝘁𝗲 𝗣𝗮𝗽𝗲𝗿: 𝗔𝗱𝗮𝗽𝘁𝗶𝗻𝗴 𝗮 𝗥𝗲𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗖𝗼𝗺𝗽𝗲𝘁𝗲𝗻𝘁 𝗔𝗱𝗲𝗻𝗼-𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝗩𝗶𝗿𝘂𝘀 (𝗿𝗰𝗔𝗔𝗩) 𝗔𝘀𝘀𝗮𝘆 𝗳𝗼𝗿 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴   Looking to dive deep into the mechanics of Adeno-Associated Virus (AAV) production and analytical testing? We have just released a white paper from SK pharmteco's Virology, Testing & Analytical Services, and Viral Vector Research and Development teams. This comprehensive guide offers a detailed analysis of the triple transfection method for generating recombinant AAV (rAAV) and the required safety testing (rcAAV) that is available at SK pharmteco, critical for gene therapy applications. https://lnkd.in/gjKB9TqC #CellAndGeneTherapy #AnalyticalTesting #rcAAV #Biotech #Pharmaceuticals #Innovation #CGMP #viralvector #virology

COMMON BIOPROCESSING CHALLENGES CAN BE OVERCOME WHEN PRODUCING VIRAL VECTORS The production of monoclonal antibodies (mAbs) and viral vectors both rely on a similar process. So what can manufacturing mAbs teach us about scaling up the production of viral vectors? Suparna Sanyal, a cell and gene expert at Lonza, gives her thoughts on how common bioprocessing challenges can be overcome when producing viral vectors. Read the full article in PharmTech: https://lnkd.in/efb5K7qQ

Check out our latest white paper, about rcAAV testing performed by my group!

The production of monoclonal antibodies (mAbs) and viral vectors both rely on a similar process. So what can manufacturing mAbs teach us about scaling up the production of viral vectors? Suparna Sanyal, a cell and gene expert at Lonza, gives her thoughts on how common bioprocessing challenges can be overcome when producing viral vectors. Read the full article in PharmTech: https://lnkd.in/efb5K7qQ #AHealthierWorld #CellTherapy #ViralVectors #PharmaceuticalManufacturing

check this out, highlights of our sequencing applications for GT

Our team is preparing for World Vaccine Congress Europe next week! We will be showcasing our latest technologies for improving the performance, safety, and stability of vaccines and gene therapies. If you are attending, please reach out to schedule a time to meet with us to discuss how we can help you achieve your vaccine and gene therapy development goals. We can provide expert advice and guidance on a wide range of topics, including: - Eliminating the headaches of serum and serum protein - Formulation and stabilization - Quality control and testing - Cell culture and scale-up How can we help you? Our team has a deep understanding of the challenges involved in developing and manufacturing cell-based vaccines and gene therapies. We also have a wide range of technologies that are incorporated in on-market clinical products. For example, we can provide animal-free recombinant proteins that are specifically designed for vaccines and gene therapies. In addition, we can provide you with formulation and stabilization solutions that can help to protect product potency and extend shelf life while reducing the challenges with cold chain management. We would be happy to schedule a time to discuss your specific needs and how we can help you to achieve your goals. #WVCEU #Vaccinenation #AOF #CMC

🌟 AAV Production Using Microcarriers Shows Higher Viral Production Yield than Suspension Culture 🌟 Delighted to share a pivotal study by Yongfa Lan, HaiRui Yang, and QingRui You from Obio Technology, in collaboration with Cytiva. This research highlights the effectiveness of microcarriers in producing adeno-associated virus (AAV) using HEK293T cells. 🧬 Key Insights: 🔬 Microcarriers vs Traditional Methods: The study reveals a striking 3.2 times higher yield in viral production using microcarriers compared to suspension cultures. 📈 Scalability and Efficiency: Beyond the increased yield, microcarriers offer scalable and efficient solutions for enhancing viral production. Significance: 💡 This study is a breakthrough for those aiming to upscale their production of viral vectors. It marks a significant advancement in gene therapy and biotechnological production. 🤝 Interested in boosting your production capabilities? Are you interested in upscaling viral production of adherent cells? Get in touch with us to learn more about our unique microcarrier offerings. #Cytiva #GeneTherapy #Biotech #Innovation #Microcarriers #ViralProduction #HEK293T #Biotechnology Read More: https://lnkd.in/gXgMCRpX

#ProductHighlight! Contamination with #Mycoplasma represents one of the greatest threats to #cellculture, as they can have deleterious effects on cultured cells by competing for nutrients, altering ATP levels and eliciting global changes in the cells' gene expression profile. The MycoGenie Rapid Mycoplasma Detection Kit by our partner Assay Genie enables the fast and simple detection of mycoplasma contamination in cell culture. This novel system detects mycoplasma in 1 hour from 1 µl of cell culture supernatant by visual determination eliminating the requirement for PCR, qPCR, electrophoresis or ELISA. ➡ https://lnkd.in/erzMnQU9 Compared with PCR, the MycoGenie Rapid Mycoplasma Detection Kit is more resistant to cell culture inhibitors, thus avoiding false positive and false negative results. The kit can detect up to 28 mycoplasma species, including 8 of the most common species associated with cell culture contamination. It is suitable for mycoplasma detection in a wide range of suspension and adherent cells including CHO, Vero, hybridoma, Sf9, HEK293 and many more. In our webshop, you can now save 50% on the MycoGenie Rapid Mycoplasma Detection Kit from Assay Genie. #biomol #assaygenie #cellbiology #antibodyproduction #celltherapy #youhavethevisionwehavethesubstance

CRISPR gene editing can revolutionize the creation and optimization of cell lines, propelling the biotherapeutics sector into a new era of innovation. In a rapidly evolving biotherapeutics landscape, CDMOs are embracing CRISPR technology to overcome challenges in cell line development. With a projected $1.7 billion market by 2028, the demand for improved biotherapeutics is driving CDMOs to streamline processes. From improving protein production to simplifying downstream processing, CRISPR's versatility positions CDMOs at the forefront of biotherapeutic advancement. The article emphasizes the urgency for CDMOs to fully embrace CRISPR or risk falling behind in the fast-growing global biotherapeutics industry. https://lnkd.in/gzdvHzbf